Novartis trial failure raises stakes for Amgen and Eli Lilly in Lp(a) drug race
Blood sample for a lipoprotein(a) test. Md Babul Hosen | Istock | Getty Images Novartis‘ failure in a closely watched cardiovascular trial has raised questions about one of the pharmaceutical industry’s biggest drug races and rival treatments from U.S. heavyweights Amgen and Eli Lilly. The pelacarsen drug, developed jointly with Ionis Pharmaceuticals, reduced a particularly…